Pharmaceutical

Galecto terminates development for its lead candidate

The Phase IIb trial in idiopathic pulmonary fibrosis for GB0139 did not meet its endpoint, leading Galecto to abandon development.

Aug 16, 2023 - 20:00
Galecto terminates development for its lead candidate
The Phase IIb trial in idiopathic pulmonary fibrosis for GB0139 did not meet its endpoint, leading Galecto to abandon development.
Read the original article

Tags:

Previous Article

Amicus gears up to launch Pompe disease combination therapy in the UK

Next Article

Signal: Illumina under investigation by SEC over $8bn Grail acquisition

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Rigosertib sodium by Traws Pharma for Epidermolysis Bul...

Apr 19, 2024

STAT+: DarioHealth acquires Twill, hoping it’s a shortcut to profitability

STAT+: DarioHealth acquires Twill, hoping it’s a shortc...

Feb 21, 2024

Jazz’s cannabidiol therapy flunks in Japanese Phase III trial

Jazz’s cannabidiol therapy flunks in Japanese Phase III...

Aug 25, 2024